Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340586 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01340586 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 18 participants.
The verdict
NCT01340586, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacokinetics of a single oral dose of 5 mg Apixaban in subjects with normal renal function and subjects with end stage renal disease (ESRD) maintained with hemodialysis.
Interventions
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01340586
The ClinicalTrials.gov registry entry for NCT01340586 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apixaban is the first listed.
NCT01340586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01340586 about?
NCT01340586 is a clinical study titled "Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis". The purpose of this study is to assess the pharmacokinetics of a single oral dose of 5 mg Apixaban in subjects with normal renal function and subjects with end stage renal disease (ESRD) maintained with hemodialysis.
What is the current status of trial NCT01340586?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-06. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01340586?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT01340586?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.